Jesse is a seasoned leader in the biopharmaceutical development field, with over two decades of experience across various roles in companies like Lonza, Cytovance Biologics, and Wheeler Bio. With a robust background spanning both private and public enterprises, he has successfully navigated P&L responsibilities while showcasing versatile leadership across multiple domains including innovation, development, manufacturing, supply chain, quality assurance, regulatory affairs, finance, and commercial operations. During his tenure as Chief Technology Officer at Cytovance Biologics in Oklahoma City, Jesse played a crucial role in driving remarkable growth, tripling the company's top-line revenue over five years and significantly boosting EBITDA by expanding commercial manufacturing capabilities. His leadership as CEO was instrumental in guiding Cytovance through a successful IPO in 2020, raising $585 million USD for the parent company. Following his impactful seven-year journey at Cytovance, Jesse ventured into entrepreneurial endeavors as an entrepreneur-in-residence at Echo Investment Capital. Here, he co-founded Wheeler Bio in 2021, focusing on clinical-scale manufacturing, a testament to his commitment to advancing the industry. Jesse's academic background is equally impressive, holding a Ph.D. in Microbiology from the University of Massachusetts, complemented by postdoctoral work at Dartmouth. His contributions to academia include authoring over 25 peer-reviewed journal articles and book chapters, alongside being a sought-after presenter at industry conferences. Despite being a New England native, Jesse has made Oklahoma City his home since 2013, where he resides with his family.